|
|
|
GILD Forecast
Recent GILD Price |
|
GILD Forecast Price |
$65.33 |
+26.83% |
$82.86 |
As of 2024-05-03
Recent GILD Analyst Ratings Breakdown |
|
Current |
1 Mo. Ago |
2 Mo. Ago |
3 Mo. Ago |
Strong buy ratings: |
10 |
10 |
10 |
11 |
Buy ratings: |
0 |
0 |
0 |
0 |
Hold ratings: |
14 |
14 |
14 |
11 |
Sell ratings: |
0 |
0 |
0 |
0 |
Strong sell ratings: |
0 |
0 |
0 |
0 |
Average rating: |
2.17 |
2.17 |
2.17 |
2.0 |
In the last row of the above table, the average rating presented is from 1 to 5 where 1 means Strong Buy and 5 means Strong Sell.
For the Gilead Sciences Inc forecast (traded under symbol GILD) for one year forward price target at the top of this page, we have presented the average GILD forecast for forward target price across the 22 analysts covering GILD, as reported in
data provided by Zacks Investment Research via Quandl.com.
Meanwhile, note that the
median GILD forecast price target (median being the middle where half of analysts had a higher GILD forecast and half had a lower GILD forecast, which is a different metric than the average or mean) was $80.0 as of 2024-05-03, while the
highest GILD forecast in the analyst group was $105.0, and the lowest GILD forecast in the analyst group was
$69.0, with a standard deviation of $9.223. Get the latest Zacks research report on GILD — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Name: |
Gilead Sciences Inc |
Stock buyback: |
GILD buyback |
Website: |
www.gilead.com |
Sector: |
Biotechnology |
Number of ETFs Holding GILD: |
132 (see which ones) |
Total Market Value Held by ETFs: |
$12,755,955,891.9 |
Total Market Capitalization: |
$81,611,000,000 |
% of Market Cap. Held by ETFs: |
15.63% |
|
|
|
|
Buy (2.83 out of 4)
25th percentile
|
PARTNER NEWS:Fri, May 3, 3:08 AM, Zacks
The Zacks Analyst Blog Highlights Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine Gilead Sciences, GSK, Deciphera, Bristol Myers and Editas Medicine are included in this Analyst Blog.
Thu, May 2, 8:02 AM, Zacks
Biotech Stock Roundup: GILD's GSK' Q1 Earnings, DCPH Soars on Acquisition News & More Deciphera Pharmaceuticals, Inc. (DCPH) and GSK are in focus on acquisition news and Q1 earnings, respectively.
|
|